License and Supply Agreement Worth KRW 39 Billion Signed

Dongkook Pharmaceutical has signed a license and supply agreement for 'UreSco Tab', an improved fixed-dose combination drug for the treatment of benign prostatic hyperplasia (BPH).


On July 2, Dongkook Pharmaceutical announced that it has entered into a license and supply agreement for UreSco Tab worth a total of KRW 39 billion over the next 10 years with FAES FARMA, a global pharmaceutical company based in Spain, covering 13 countries in Central and South America including Mexico, Colombia, Ecuador, Peru, and Chile.


Dongkook Pharmaceutical Cheongdam Building, Gangnam-gu, Seoul. Dongkook Pharmaceutical

Dongkook Pharmaceutical Cheongdam Building, Gangnam-gu, Seoul. Dongkook Pharmaceutical

View original image

FAES FARMA plans to sequentially proceed with product approval processes in the contracted countries and launch the product upon completion of approvals. Dongkook Pharmaceutical also plans to expand the agreement to additional countries such as Brazil, thereby establishing a foundation for mid- to long-term business expansion.



A Dongkook Pharmaceutical representative stated, "The entry of UreSco into the Central and South American market marks the first step toward the global expansion of the world's first fixed-dose combination drug for BPH treatment," adding, "By expanding partnerships to various regions and building a sustainable business foundation in the BPH treatment market, this will serve as a meaningful turning point to demonstrate our product's outstanding competitiveness to the global market."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing